Analysts rate Bionano Genomics Inc. (BNGO:NSD) with a Strong Buy rating and a $9.50 target

STA Research
by: STA Research
BNGO Stock

Based on the Bionano Genomics stock forecast from 2 analysts, the average analyst BNGO stock price target is USD 9.50 over the next 12 months. Bionano Genomics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BNGO stock forecast is Bearish, which is based on 1 positive signal and 5 negative signals. At the last closing, Bionano Genomics stock price was USD 1.90Bionano Genomics stock price has changed by -0.45% over the past week, -0.65% over the past month and -66.31% over the last year.


About Bionano Genomics Inc. (BNGO:NSD):

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company was founded in 2003 and is headquartered in San Diego, California.


Most Recent Analyst Ratings for BNGO’s stock:

Resumed Oppenheimer Holdings Outperform USD 12 2022-07-18
Target Lowered by BTIG Research USD 10 » USD 7 2022-04-07
Reiterated by Oppenheimer Outperform » Outperform USD 14 2021-12-30
Initiated by Maxim Group Buy USD 12 2021-11-06
Initiates Coverage On BTIG Research Buy USD 10 2021-06-16
Reiterated by Oppenheimer Holdings Buy USD 15 2021-03-24
Target Raised by Oppenheimer Holdings USD 1.5 » USD 15 2021-02-08
Target Raised by Ladenburg Thalmann Buy USD 1.25 » USD 14 2021-01-27
Target Raised by Maxim Group USD 2 » USD 14 2021-01-22
Downgraded by Roth Capital Buy » Neutral 2020-12-04
Initiated by Ladenburg Thalmann Buy USD 1.25 2020-09-24
Reiterated by Oppenheimer Holdings Buy 2020-08-24
Initiated by Maxim Group Buy USD 2 2020-07-12
Reiterated by Roth Capital Buy USD 1 2020-06-04
Initiated by Oppenheimer Holdings Outperform USD 1.5 2020-04-08
Reiterates Maxim Group Buy USD 3 2019-11-09
Reiterates Maxim Group Buy USD 3 2019-11-08
Reiterates Maxim Group Buy USD 11 2019-06-20
Upgrades Maxim Group Buy USD 11 2019-03-06
Initiates Roth Capital Buy USD 12 2018-09-26
Initiates Maxim Group Buy 2018-09-25


What we like:

Superior risk adjusted returns:

BNGO stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.


What we don’t like:

High volatility:

The total returns for BNGO stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value:

BNGO stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

Bionano Genomics had negative total cash flow in the most recent four quarters.

Negative free cash flow:

Bionano Genomics had negative total free cash flow in the most recent four quarters.

Low Earnings Growth:

BNGO stock has shown below median earnings growth in the previous 5 years compared to its sector.




Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.